Key takeaways
- Lyophilization (freeze-drying) removes water by sublimation, leaving a stable solid “cake” for long-term storage.
- Reconstitute gently: add solvent down the vial wall, swirl — never shake — and let it dissolve fully.
- A good cake is uniform and intact; collapse or shrinkage can signal a compromised lyophilization cycle.
Most research-grade peptides arrive as a white or off-white lyophilized (freeze-dried) cake or powder inside a sterile vial. Before use, the material must be reconstituted into solution. The reconstitution step seems trivial — add water, swirl, done — but small choices about solvent, concentration, temperature, and handling have measurable consequences for peptide stability and assay reproducibility.
Why peptides ship lyophilized
Lyophilization removes water from the peptide by sublimation under vacuum at low temperature. The resulting amorphous solid has dramatically reduced rates of hydrolysis, oxidation, and microbial growth compared to an aqueous solution. A well-lyophilized peptide stored at −20 °C in its original sealed vial is stable for years; the same peptide reconstituted at room temperature might degrade in days.
The trade-off is that the researcher takes on responsibility for the reconstitution step. Suboptimal reconstitution — wrong solvent, vigorous shaking, concentration too high or too low — can compromise even a perfectly synthesized batch.
Choosing a reconstitution solvent
The three most common reconstitution solvents for research peptides are:
- Sterile water for injection (SWFI): water that has been sterilised by filtration or autoclaving. Single-use; once the vial is opened, microbial growth in the residual solvent is unconstrained.
- Bacteriostatic water for injection (BAC water): water containing 0.9% benzyl alcohol as a preservative. The preservative inhibits bacterial growth, enabling multi-day or multi-week use of the same reconstituted vial. This is the standard solvent for multi-use research peptides.
- Acetic acid (typically 0.1–1% aqueous): used for peptides that are poorly soluble at neutral pH, particularly those with high isoelectric points or hydrophobic residues. The acidic pH improves solubility.
- Tang, X., Pikal, M. J. (2004). Design of freeze-drying processes for pharmaceuticals. Pharmaceutical Research, 21(2), 191-200. DOI: 10.1023/B:PHAM.0000016234.73023.75.
Choose based on (a) the duration of the experiment, (b) the solubility of the peptide, and (c) the assay’s tolerance for the solvent. For most multi-day research protocols, BAC water is the default.
Concentration considerations
Stock concentrations of 1–5 mg/mL are typical for soluble research peptides. Higher concentrations may be needed for poorly soluble peptides or assays requiring small volumes. The maximum practical concentration is set by the peptide’s solubility at the reconstitution pH and the volume of the vial.
A note on dead volume: when a sterile vial contains a stopper and the cake adheres to the bottom, the practical reconstitution volume is slightly less than the rated vial volume. Aim to reconstitute to slightly below the stated volume to avoid overfilling.
The reconstitution procedure
The recommended procedure for most peptides:
- Allow the lyophilized vial to come to room temperature (10–15 minutes from refrigerator). Cold vials condense ambient moisture on the inner surface, potentially altering the reconstitution.
- Calculate the volume of solvent required for the target stock concentration. For example, 5 mg peptide at 5 mg/mL stock requires 1.0 mL solvent.
- Using a sterile syringe with a fine-gauge needle, slowly inject the solvent down the side of the vial, allowing it to flow over the cake. Do not direct the solvent stream at the cake — this can cause foaming and air entrainment.
- Allow the cake to dissolve passively for 30–60 seconds. Most peptides go into solution rapidly with no agitation required.
- If a residue remains, gently swirl the vial in a slow rotation. Never shake vigorously — shaking introduces air bubbles, causes peptide aggregation at the air-water interface, and can lead to denaturation of lipidated or large peptides.
- Inspect the solution. It should be clear, colorless (or pale blue for copper-coordinated peptides like GHK-Cu), and free of visible particulates.
Common reconstitution problems
Cloudy or hazy solution: indicates aggregation, microparticle formation, or precipitation. For poorly soluble peptides, try reconstituting in dilute acetic acid (0.1%) instead of pure water. For lipidated peptides, ensure the temperature is at or above room temperature.
Foaming during reconstitution: indicates the solvent was injected too forcefully or the vial was shaken. Foaming concentrates peptide at the air-water interface and accelerates aggregation. If this occurs, allow the foam to settle for 30 minutes before use, or repeat reconstitution with a fresh vial.
Cake doesn’t dissolve: may indicate over-vacuum or partial degradation. Try gentle warming to 30–37 °C (not above). If the cake remains, contact the supplier — the lot may have a manufacturing issue.
Post-reconstitution handling
Once reconstituted, store the solution at 2–8 °C in the original vial. Aliquot to working concentrations using sterile technique. For experiments spanning multiple days, BAC water-reconstituted solutions are typically stable for 14–28 days at 2–8 °C, depending on the peptide chemistry. Sensitive peptides (e.g. NAD+, lipidated incretins) have shorter reconstituted shelf life and should be used within 7–14 days.
Repeated freeze-thaw of reconstituted peptide is discouraged — each freeze-thaw cycle causes some loss to aggregation. If long-term storage of reconstituted material is needed, aliquot at the time of reconstitution and freeze once.
References & further reading
- Carpenter, J. F., Pikal, M. J., Chang, B. S., Randolph, T. W. (1997). Rational design of stable lyophilized protein formulations: some practical advice. Pharmaceutical Research, 14(8), 969–975.
- Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics, 203(1-2), 1–60. DOI: 10.1016/S0378-5173(00)00423-3.
- USP General Chapter <1207> — Sterile Product Packaging — Integrity Evaluation. United States Pharmacopeia.
- Pikal, M. J., Roy, M. L., Shah, S. (1984). Mass and heat transfer in vial freeze-drying. Journal of Pharmaceutical Sciences, 73(9), 1224-1237. DOI: 10.1002/jps.2600730910.
- Wang, W., Chen, M., Chen, G. (2014). Issues in freeze-drying of peptides and proteins. BioPharm International, 27(2), 26-32. DOI: 10.1016/j.ejpb.2014.09.005.
- Patel, S. M., Doen, T., Pikal, M. J. (2010). Determination of end point of primary drying in freeze-drying. AAPS PharmSciTech, 11(1), 73-84. DOI: 10.1208/s12249-009-9362-7.
- Searles, J. A., Carpenter, J. F., Randolph, T. W. (2001). The ice nucleation temperature determines the primary drying rate. Journal of Pharmaceutical Sciences, 90(7), 860-871. DOI: 10.1002/jps.1041.
- Frokjaer, S., Hovgaard, L. (2000). Pharmaceutical Formulation Development of Peptides and Proteins. Taylor & Francis. DOI: 10.1201/9780203482209.